CDK1 inhibitors currently are not available for sarcomas, as well as CDK4/6 targeted inhibitors such as palvociclib and ribociclib which are approved for breast cancer by the US Food and Drug Administration (FDA) also have not been approved yet for sarcomas. The gene discussed is CDK4; the disease is sarcoma.